Malaria’s parasites hide in the liver before wrecking red cells
Malaria spreads when infected female Anopheles mosquitoes inject Plasmodium parasites. Symptoms usually start ten to fifteen days later—fever, fatigue, vomiting, headache—and can progress to jaundice, seizures, coma, or death. In 2024, about 282 million cases caused an estimated 610,000 deaths, with roughly ninety-five percent in sub-Saharan Africa.
Five Plasmodium species commonly infect humans; P. falciparum drives most deaths, with P. vivax and zoonotic P. knowlesi also able to turn severe, while P. ovale and P. malariae are usually milder. Among infections, falciparum is identified in about seventy-five percent and vivax in about twenty percent. Sporozoites travel to the liver and multiply silently—each hepatocyte eventually holding up to 40,000 parasites—before merozoites burst into blood, invade red cells, and amplify every twenty-four to seventy-two hours. Symptoms appear once density exceeds roughly 100,000 parasites per millilitre. P. vivax and P. ovale can leave dormant hypnozoites that relapse weeks or months later.
Falciparum-infected red cells sprout adhesive proteins that clog capillaries and seed organ failure. Cerebral malaria can kill within forty-eight hours of neurological symptoms if untreated. Severe anaemia from destroyed cells plus failed marrow production is a major killer of children under five. Acute respiratory distress hits up to twenty-five percent of cases and kills about forty percent of affected adults once breathing fails. Pregnancy raises stillbirth, miscarriage, and low-birth-weight risks. The medieval Italian name mala aria—“bad air”—recalls older swamp theories; English used the word by at least 1768.
Prevention leans on nets, repellents, insecticide spraying, draining standing water, and prophylactic drugs. As of 2023 the World Health Organization had endorsed two malaria vaccines. Diagnosis still relies mainly on blood films or antigen rapid tests; PCR exists but remains costly for endemic clinics. Resistance complicates care: chloroquine-resistant falciparum covers most malaria zones, and artemisinin resistance troubles parts of Southeast Asia, so regimens must match species and geography. Africa’s 2005 estimated annual loss of twelve billion U.S. dollars from care costs, lost work, and tourism damage shows how a mosquito bite scales into an economy.
Source: Malaria
